Tirzepatide Dosing Schedule: A Week-by-Week Titration Guide

What Is Tirzepatide Titration?

Tirzepatide is not started at its maximum dose. Instead, patients begin at a low starting dose and gradually increase — a process called titration. The purpose is to allow your body to adapt to the medication's effects, particularly the gastrointestinal effects like nausea that are most common during dose escalation. Titrating slowly significantly reduces the likelihood and severity of side effects during treatment.

The Standard Tirzepatide Dosing Schedule

The standard titration protocol used for brand-name tirzepatide products (Mounjaro® and Zepbound®) and as the basis for compounded tirzepatide programs is as follows:

• Weeks 1–4: 2.5 mg weekly — The starting dose. Used exclusively for tolerability; meaningful weight loss is not expected at this dose.
• Weeks 5–8: 5 mg weekly — First maintenance-range dose. Most patients begin noticing appetite suppression here.
• Weeks 9–12: 7.5 mg weekly — Continued escalation; most patients tolerate well with simple dietary strategies in place.
• Weeks 13–16: 10 mg weekly — Middle of the therapeutic range. Significant weight loss is typically ongoing at this stage.
• Weeks 17–20: 12.5 mg weekly — Near maximum dose. Some patients achieve their target results at this level.
• Week 21+: 15 mg weekly — The highest approved dose. The SURMOUNT-1 trial used this dose and showed an average of 22.5% body weight loss over 72 weeks.

Each dose level is maintained for approximately four weeks before advancing. Your provider may adjust this timeline based on how you are tolerating the current dose.

Why Slow Titration Matters

The most common reason patients discontinue GLP-1 medications early is GI side effects — nausea, vomiting, and stomach discomfort. These effects are dose-dependent and most pronounced during dose increases. Slow titration dramatically reduces their impact by giving your digestive system time to adapt.

Clinical trial data confirm that patients who advance gradually through the titration schedule experience fewer treatment discontinuations. Your provider will work with you to find a pace that keeps you comfortable. For a full overview of what to expect, see our tirzepatide side effects guide.

Signs You Are Ready to Advance Your Dose

Your provider will advise on timing, but generally the signals to advance to the next dose level include:

• Tolerating your current dose well — minimal nausea or GI discomfort
• Appetite suppression has plateaued — you do not feel as full or satisfied as when you first started the dose
• Weight loss rate has slowed noticeably at your current dose
• You have completed the minimum four weeks at the current dose

Signs to Stay at Your Current Dose Longer

It is sometimes medically appropriate to pause at a dose level rather than advance on schedule. Consider staying at your current dose if you are experiencing significant nausea, vomiting, or diarrhea that has not resolved, or if you are managing a concurrent illness. Discuss any decision to pause or extend with your provider — never adjust your dosing schedule without provider guidance.

What If You Miss a Dose?

Tirzepatide is a once-weekly injection. If you miss your scheduled injection:

• If your next scheduled injection is more than four days away, take the missed dose as soon as you remember.
• If your next scheduled injection is within four days, skip the missed dose and resume your regular schedule.
• Do not take two doses in one week to make up for a missed injection.

After missing a dose or being off the medication for two or more weeks, your provider may recommend repeating a lower dose before advancing again, as your tolerance can partially reset after a gap in treatment.

Practical Tips for Staying on Schedule

• Choose a consistent injection day — Sunday evening or Monday morning works well for many patients, placing any adjustment period earlier in the week when it is easier to manage.
• Set a weekly phone reminder on the same day and time each week.
• Store medication correctly — refrigerate at 36–46°F and allow to come to room temperature for 30 minutes before injecting to reduce discomfort.
• Keep a simple dose log — record the date, dose, and any side effects. This data helps your provider make informed titration decisions.

Compounded Tirzepatide and Dosing

Compounded tirzepatide is prepared by state-licensed compounding pharmacies using the same active ingredient as brand-name products. Compounded tirzepatide is different from FDA-approved branded products such as Zepbound® and Mounjaro® and has not been evaluated by the FDA for safety, efficacy, or quality. Formulation, strength, and inactive ingredients may differ from the FDA-approved branded versions.

Dosing schedules for compounded tirzepatide typically mirror the brand-name protocol — starting at 2.5 mg and titrating to a maximum of 15 mg weekly. Your AvataCore provider will establish your specific dosing schedule and monitor your progress at each milestone. See our compounded tirzepatide guide for details on how the compounding process works and what quality standards matter.

What to Expect at Each Stage

Understanding the typical experience at each dose level helps you stay committed during the early months:

• Month 1 (2.5 mg): Minimal weight loss is expected; the focus is tolerability. Some patients experience early appetite suppression.
• Month 2–3 (5–7.5 mg): Most patients begin noticing meaningful appetite suppression. Weight loss of 2–5% is common by the 8–12 week mark.
• Month 4–5 (10–12.5 mg): Weight loss accelerates for most patients. Many providers consider this the high-impact therapeutic range.
• Month 5–6+ (15 mg): Maximum dose for maximum effect. The SURMOUNT-1 trial measured outcomes at 72 weeks, and results continue to accumulate well beyond month 3.

For a month-by-month breakdown of expected weight loss outcomes, see our tirzepatide results timeline. Current plan pricing is available at AvataCore pricing.